Chinese Universities Achieve World's First Stem Cell Reversal of Type 1 Diabetes

Chinese Universities Spearhead Stem Cell Breakthrough for Type 1 Diabetes

Researchers from leading Chinese institutions have made medical history by achieving the world's first successful reversal of type 1 diabetes (T1D) using stem cell therapy. This landmark accomplishment highlights China's growing dominance in regenerative medicine, with universities like Peking University and Naval Medical University at the forefront. The innovation promises to transform lives for millions affected by this autoimmune condition, where the body's immune system destroys insulin-producing beta cells in the pancreas, forcing lifelong insulin dependence.

Type 1 diabetes impacts approximately 1.4 million people in China alone, part of a global figure exceeding 8.4 million cases. Traditional management relies on daily insulin injections, continuous glucose monitoring, and strict diet control, but complications like hypoglycemia, cardiovascular disease, and kidney failure remain common. The new therapy addresses the root cause by regenerating functional islet cells, offering hope for a functional cure.

Understanding Type 1 Diabetes and Its Burden

Type 1 diabetes is an autoimmune disease typically diagnosed in childhood or adolescence, though adult-onset cases are rising. In China, incidence rates have climbed from 0.18 per 100,000 in earlier decades to around 1 per 100,000 today, driven by genetic, environmental, and lifestyle factors. Patients face daily challenges: calculating carbohydrate intake, managing blood sugar fluctuations, and avoiding severe events like diabetic ketoacidosis.

Economically, T1D costs China billions annually in healthcare, lost productivity, and complications treatment. Universities play a pivotal role here, with government funding surging for biomedical research—over 100 billion RMB invested in stem cell initiatives since 2020. This support has positioned Chinese academics as global leaders.

China's Stem Cell Research Ecosystem

China boasts world-class facilities and talent pools in stem cell biology. Institutions receive substantial National Natural Science Foundation grants and 'Double First-Class' status, fostering interdisciplinary teams of biologists, engineers, and clinicians. Peking University and Naval Medical University exemplify this, collaborating with the Chinese Academy of Sciences (CAS) on cutting-edge protocols.

Key enablers include advanced bioreactors for cell scaling, CRISPR-free chemical reprogramming to sidestep ethical issues, and rapid clinical trial approvals via platforms like Boao Lecheng. These efforts have yielded over 47% of global immune cell therapy trials originating from China.

Peking University's Pioneering Role

At Peking University School of Life Sciences, Professor Deng Hongkui's team pioneered chemically induced pluripotent stem cells (CiPSCs). Unlike traditional iPSCs using viral vectors, CiPSCs employ small molecules for safer reprogramming, reducing cancer risk.

In a landmark Cell study, they treated a 25-year-old woman with 11 years of T1D. Her peripheral blood cells were converted to CiPSCs, differentiated into 1.2 million islet equivalents, and transplanted under the abdominal skin—a minimally invasive site avoiding the liver's harsh environment.

Naval Medical University's Clinical Excellence

Naval Medical University, through Shanghai Changzheng Hospital, led the first type 2 diabetes (T2D) reversal in a 59-year-old man post-liver transplant. Using endoderm stem cells (EnSCs) from fat tissue, they generated autologous islets transplanted subcutaneously. The patient achieved insulin independence for over 33 months.

Extending to T1D, their E-islet platform—derived from non-proliferative EnSCs—treated multiple patients. A Lancet Diabetes & Endocrinology paper detailed three cases: a 30-year-old woman, 45-year-old man, and 15-year-old girl, all regaining glycemic control with reduced or no insulin.

Step-by-Step: How the Therapy Works

The process exemplifies precision medicine:

• Cell Harvesting: Autologous peripheral blood mononuclear cells or adipose-derived cells collected minimally invasively.
• Reprogramming: Chemical cocktails convert somatic cells to pluripotent or endoderm stem cells in 2-5 weeks, bypassing genetic modification.
• Differentiation: Stem cells guided to pancreatic progenitors, then to beta, alpha, delta, and PP cells mimicking natural islets (50-60% beta cells).
• Quality Control: Rigorous testing for purity (>95%), viability, glucose responsiveness, and no off-target cells.
• Transplantation: 1-2 million islet equivalents injected under skin or portal vein, often with short-term immunosuppression.
• Monitoring: C-peptide levels, HbA1c, continuous glucose monitoring track engraftment and function.

Vascularization occurs within weeks, enabling self-sustained insulin production.

Real-World Case Studies from Chinese Labs

The Peking University case: Post-transplant, the patient's time-in-range (TIR, 3.9-10 mmol/L) reached 98%, HbA1c dropped to 5.9%, with robust C-peptide response. No serious adverse events over 1+ year.
For details on the protocol, explore the Cell publication.

Naval Medical University's series: Patient 2 (allogeneic) achieved 100% TIR, insulin-free by month 11. Patient 3 reduced insulin 70%. Even autologous grafts showed promise, though one failed due to autoimmunity recurrence.
See the Lancet findings here.

Addressing Risks and Challenges

While transformative, hurdles persist:

• Teratoma Risk: Mitigated by non-integrative chemical methods and non-pluripotent EnSCs.
• Immune Rejection: Autologous preferred; allogeneic needs immunosuppression, risking infections.
• Scalability: Producing billions of cells cost-effectively; current yields ~20-30% viable islets.
• Long-Term Durability: 1-3 year data promising, but lifelong monitoring needed.
• Autoimmunity Recurrence: T1D patients' immune systems may attack new islets; protective encapsulation explored.

Experts like Prof. Deng note, "This is a functional cure, but larger trials are essential." International regulators echo caution for widespread use.

Global Implications and Collaborations

China's advances outpace Vertex Pharmaceuticals' VX-880 trial (US), inspiring partnerships. Peking and Naval Medical Universities host international fellows, sharing protocols. The WHO praises potential for low-resource settings, where T1D mortality is high.

Read more on global trials at ClinicalTrials.gov.

Career Opportunities in China's Regenerative Medicine

These breakthroughs spur demand for experts in stem cell engineering, immunology, and bioethics. Peking University offers PhD programs in life sciences; Naval Medical University recruits postdocs. Funding via NSFC exceeds 500 million RMB yearly, with salaries 200,000-500,000 RMB for faculty.

• Research assistantships in islet differentiation.
• Clinical trial coordinators at affiliated hospitals.
• Bioinformatics for cell quality control.

Future Outlook: Scaling to Millions

By 2029, allogeneic E-islets may gain approval, slashing costs from 1 million RMB to accessible levels. Universities plan Phase II/III trials for 100+ patients. Integration with AI for personalized dosing and gene editing for immune evasion looms.

China's higher education sector, with 3,000+ universities emphasizing STEM, positions the nation to eradicate T1D burdens, fostering a new era of precision health.

Photo by Lan Lin on Unsplash